FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ramin Ebrahimi

Research Profile

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Interactions

Procedures

Double-Blind Method

Disorders

Activities & Behaviors

Patient Compliance

Living Beings

HIV-1

Co-author Network

Publications

TOP 3
Oliver A Cornely; Emma Dellow; Ramin Ebrahimi; Raoul Herbrecht; Johan Maertens; Mark Bresnik; J Peter Donnelly
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Oliver A Cornely; Johan Maertens; M Bresnik; Andrew J Ullmann; Ramin Ebrahimi; Raoul Herbrecht
Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B.
Richard Elion; Calvin Cohen; Douglas Ward; Peter Ruane; Roberto Ortiz; Y Sunila Reddy; Ramin Ebrahimi; Damian McColl; Brian Kearney; Alvan Fisher; John Flaherty
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ramin Ebrahimi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Oliver A Cornely; Emma Dellow; Ramin Ebrahimi; Raoul Herbrecht; Johan Maertens; Mark Bresnik; J Peter Donnelly
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Mycoses 2011;54(5):e449-55.
2010: Oliver A Cornely; Johan Maertens; M Bresnik; Andrew J Ullmann; Ramin Ebrahimi; Raoul Herbrecht
Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B.
The Journal of antimicrobial chemotherapy 2010;65(1):114-7.
2008: Richard Elion; Calvin Cohen; Douglas Ward; Peter Ruane; Roberto Ortiz; Y Sunila Reddy; Ramin Ebrahimi; Damian McColl; Brian Kearney; Alvan Fisher; John Flaherty
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
HIV clinical trials 2008;9(4):213-24.
2008: Edwin DeJesus; Peter Ruane; Cheryl McDonald; Fernando Garcia; Shetal Sharma; Roberto Corales; Jayashree Ravishankar; Homayoun Khanlou; David Shamblaw; Janet Ecker; Ramin Ebrahimi; John Flaherty
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
HIV clinical trials 2008;9(2):103-14.
2007: Oliver A Cornely; Johan Maertens; Mark Bresnik; Ramin Ebrahimi; Andrew J Ullmann; Emilio Bouza; Claus Peter Heussel; Olivier Lortholary; Christina Rieger; Angelika Boehme; Mickael Aoun; Heinz-August Horst; Anne Thiebaut; Markus Ruhnke; Dietmar Reichert; Nicola Vianelli; Stefan W Krause; Eduardo Olavarria; Raoul Herbrecht
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(10):1289-97.
2007: C Cordonnier; M Bresnik; Ramin Ebrahimi
Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Mycoses 2007;50(3):205-9.
2006: Brian P Kearney; Anita Mathias; Angelique Mittan; John Sayre; Ramin Ebrahimi; Andrew K Cheng
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.
Journal of acquired immune deficiency syndromes (1999) 2006;43(3):278-83.
2006: Srinivasan Ramanathan; Andrew Cheng; Angelique Mittan; Ramin Ebrahimi; Brian P Kearney
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Journal of clinical pharmacology 2006;46(5):559-66.
2005: Brian P Kearney; Srinivasan Ramanathan; Andrew K Cheng; Ramin Ebrahimi; Jaymin Shah
Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
Journal of clinical pharmacology 2005;45(8):935-40.
2004: Marion G Peters; H w Hann Hw; Paul Martin; E Jenny Heathcote; P Buggisch; R Rubin; M Bourliere; Kris V Kowdley; C Trepo; D f Gray Df; M Sullivan; K Kleber; Ramin Ebrahimi; S Xiong; Carol L Brosgart
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Gastroenterology 2004;126(1):91-101.
1994: P P Harnish; H Fountaine; Ramin Ebrahimi
Iodixanol. Experience in 1,259 patients in the United States.
Investigative radiology 1994;29 Suppl 2():S236-7.